title: "Chikungunya in Europe: Record Outbreaks in 2025" date: "2026-04-03" excerpt: "Europe saw 27 chikungunya outbreaks in 2025, a new record. Learn about chronic joint pain, the IXCHIQ vaccine suspension, and how to protect your family." category: "diseases" author: "Mosticare Editorial"

Chikungunya Reaches Record Levels in Europe

By Mosticare Editorial | Published 2026-04-03

In 2025, Europe shattered its own records for chikungunya virus disease. The ECDC confirmed 27 separate outbreaks across the continent -- unprecedented in European public health history. France alone reported 480 locally acquired cases distributed across 53 clusters, while Italy documented 205 cases. For the first time, a locally acquired case was confirmed in France's Alsace region, a location previously considered too far north for transmission.

The implications are stark. Chikungunya is not merely arriving in Europe -- it is establishing itself as a seasonal reality, and the only vaccine developed to fight it has been suspended over safety concerns.

What Is Chikungunya?

Chikungunya is a viral disease transmitted by Aedes mosquitoes, primarily Aedes albopictus (the Asian tiger mosquito) in Europe. The name comes from the Kimakonde language and means "to become contorted," describing the stooped posture of sufferers due to severe joint pain.

The virus was first described during an outbreak in southern Tanzania in 1952. It circulated primarily in Africa and Asia for decades before explosive outbreaks on La Reunion island (2005-2006) and in India (2006) brought it to global attention. Europe experienced its first major outbreak in Emilia-Romagna, Italy, in 2007, with 217 confirmed cases -- a wake-up call that the continent was not immune.

The 2025 Record Season

The ECDC's seasonal surveillance data for 2025 paints a concerning picture:

France: Epicentre of the European Outbreak

As of September 2025, France reported 480 locally acquired chikungunya cases across 53 clusters, primarily in the Mediterranean regions of Provence-Alpes-Cote d'Azur and Occitanie. The sheer number of clusters -- each representing a separate chain of local transmission -- indicates that the virus was introduced by multiple viraemic travellers throughout the season, each sparking independent outbreaks.

The most alarming development was the detection of a locally acquired case in Alsace, northeastern France. This represents the northernmost autochthonous chikungunya transmission ever recorded in Europe, demonstrating that the risk zone now extends well beyond the traditional Mediterranean corridor.

Italy: Persistent Transmission

Italy recorded 205 locally acquired cases in 2025. The country has particular vulnerability due to its long-established Aedes albopictus populations and the large number of residents with connections to chikungunya-endemic regions in the Indian Ocean and South Asia.

Why 2025 Was Different

Several factors converged to produce the record season:

Expanded vector range: Aedes albopictus is now established in 369 regions across 16 EU/EEA countries, providing more geographic territory for transmission.
Earlier season onset: The 2025 mosquito season began earlier than usual, extending the window for transmission, as ECDC noted in its World Mosquito Day 2025 communication.
Increased travel: Post-pandemic travel volumes have returned to or exceeded 2019 levels, increasing the number of viraemic travellers entering Europe.
Climate conditions: Above-average temperatures and altered rainfall patterns created optimal breeding conditions across southern Europe.

The Defining Feature: Chronic Joint Pain

What makes chikungunya particularly feared -- and distinct from dengue -- is its devastating impact on joints.

Acute Phase

The initial infection typically manifests 3 to 7 days after a mosquito bite with sudden-onset high fever, severe joint pain (arthralgia), muscle pain, headache, nausea, fatigue, and rash. The acute phase usually lasts 7 to 10 days.

Chronic Phase: Months to Years of Suffering

The hallmark of chikungunya is persistent arthralgia. According to published clinical literature, 30 to 60 percent of patients experience joint pain lasting months after the initial infection, and a significant proportion report symptoms persisting for years. The joints most commonly affected are the wrists, ankles, knees, and small joints of the hands.

For many patients, chikungunya-related arthralgia is debilitating. It can prevent people from working, exercising, or performing routine daily activities. The chronic pain is often symmetrical and can closely resemble rheumatoid arthritis, sometimes leading to misdiagnosis. Anti-inflammatory medications provide only partial relief, and there is no specific antiviral treatment.

Impact on Quality of Life

The burden of chronic chikungunya arthralgia is disproportionately high for a disease perceived as "mild." Studies from previous outbreaks in the Indian Ocean region show that up to 12 percent of patients remain symptomatic three years after infection. For an ageing European population, particularly in Mediterranean countries with the highest transmission risk, this represents a significant and growing public health concern.

The IXCHIQ Vaccine: Hope Suspended

The chikungunya vaccine story is one of raised hopes and sudden reversals.

Initial Approval

In November 2023, the US FDA approved IXCHIQ (manufactured by Valneva), the first-ever chikungunya vaccine for human use. It is a live-attenuated, single-dose vaccine that generated strong immune responses in clinical trials. The European Medicines Agency subsequently authorised its use in the EU.

Safety Concerns Emerge

In early 2025, serious adverse events were reported among vaccinated individuals, particularly older adults. In France, three serious adverse events occurred in people over 80 with comorbidities. According to the UK's Medicines and Healthcare products Regulatory Agency (MHRA), IXCHIQ was subsequently restricted: it is no longer indicated for adults over 60 and is contraindicated in individuals with hypertension, cardiovascular disease, diabetes, or chronic kidney disease.

FDA Suspension

On 22 August 2025, the US FDA suspended the biologics license for IXCHIQ, citing one death from encephalitis directly attributable to the vaccine and over 20 serious adverse events, including 21 hospitalisations and 3 deaths. The Lancet Infectious Diseases has called for more transparency around the data behind the decision.

What This Means

With IXCHIQ suspended and no alternative vaccine in late-stage development, Europe faces its worst chikungunya seasons with no pharmaceutical intervention available. Prevention through mosquito bite avoidance and vector control is, for the foreseeable future, the only defence.

Prevention: What You Can Do

Personal Protection

Daytime vigilance: Aedes albopictus bites during daylight hours, with peak activity in early morning and late afternoon. This is when protection matters most.
Physical barriers: Screens on windows and doors, mosquito nets over outdoor seating areas, and protective clothing are effective, chemical-free approaches.
Eliminate breeding sites: Tiger mosquitoes breed in tiny amounts of standing water. Regularly empty flower pot saucers, vases, bird baths, and any container that collects rainwater.

If You Are Travelling

Travellers returning to Europe from chikungunya-endemic regions (Indian Ocean islands, Southeast Asia, Latin America) should take precautions for at least two weeks after returning to avoid being bitten by local Aedes mosquitoes -- thereby preventing onward transmission.

For Healthcare Providers

Given the expanding range of chikungunya in Europe, clinicians should consider chikungunya in the differential diagnosis for patients presenting with acute febrile arthralgia, particularly during the June-November transmission season, even in patients without recent travel history.

The Road Ahead

The ECDC has described the situation as a "new normal" for Europe. With 27 outbreaks in 2025, no viable vaccine, and an expanding vector population, chikungunya is poised to become a fixture of European summers. The question is not whether outbreaks will continue, but how large they will become and how far north they will reach.

For individuals and communities, the message is clear: invest in prevention now. Physical barriers, breeding site elimination, and awareness are the tools we have, and they work.

Frequently Asked Questions

How long does chikungunya joint pain last?

Acute joint pain typically lasts 1 to 2 weeks, but 30 to 60 percent of patients experience chronic arthralgia lasting months to years. Some patients report persistent symptoms more than three years after infection.

Is the chikungunya vaccine available in Europe?

IXCHIQ was approved by the EMA but has been restricted following safety concerns. It is no longer indicated for adults over 60 and is contraindicated in individuals with cardiovascular disease, diabetes, or kidney disease. The US FDA suspended its license in August 2025.

Where in Europe is chikungunya spreading?

France and Italy have reported the most locally acquired cases. In 2025, transmission reached France's Alsace region -- the northernmost case ever recorded in Europe.

About Mosticare: Mosticare develops chemical-free mosquito protection solutions for homes, businesses, and communities across Europe. Our mission: a green, mosquito-free life for every European. Learn more

Sources cited in this article: